MarketLens
Sign Up
Stock AnalysisInvestment Ideas

Is Bristol Myers Squibb's Deucravacitinib a Game-Changer for SLE Patients and BMY Investors

3 months ago
SHARE THIS ON:

Is Bristol Myers Squibb's Deucravacitinib a Game-Changer for SLE Patients and BMY Investors

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

5 months ago
Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

6 months ago
Why Are Barclays Analysts Bullish on Eli Lilly and Bristol-Myers Squibb

Why Are Barclays Analysts Bullish on Eli Lilly and Bristol-Myers Squibb

5 months ago
Why Are UnitedHealth Group and Bristol-Myers Squibb Attracting Hedge Funds

Why Are UnitedHealth Group and Bristol-Myers Squibb Attracting Hedge Funds

3 months ago

Category

TopFeaturedPro OnlyStock AnalysisInvestment IdeasETFsCrypto

You may also like

Stock News•1 week ago

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Fate Therapeutics dosed the first patient in its potentially registrational RECLAIM-LN trial of FT819 for lupus nephritis, with same-day outpatient discharge. Multiple patients are screening at activa...
FATE
Stock News•1 week ago

Systemic Lupus Erythematosus Market Report Now Available — Segments Biologics, Small Molecules, Drug Classes, Administration Routes, and Therapy Types

Systemic lupus erythematosus market is projected to reach USD 6 billion by 2035, per a new ResearchAndMarkets report covering biologics, small molecules, drug classes, routes, and therapy types.
Stock News•2 weeks ago

Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon

Roivant Sciences' $4.7B pro forma liquidity supports its shift to commercial-stage biopharma, eliminating near-term dilution risk. Brepocitinib's FDA Priority Review for dermatomyositis, with potentia...
ROIV
Stock News•1 months ago

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb's NDA for mezigdomide in relapsed/refractory multiple myeloma was accepted by the FDA, advancing a potential new treatment option.
BMY

Breaking News

View All →
Event-Driven Investing
Shareholder Rights

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

1 week ago
Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

1 week ago
Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

1 week ago

Top Headlines

View More →
Stock News•48 minutes ago

Between Amazon, Alphabet, and Meta, Microsoft is Most Likely to Deliver Best Free Cash Flow in 2026

Stock News•49 minutes ago

Amazon Web Services Backlog Reaches $496 Billion: Does That Make Amazon Stock a No Brainer Buy?

Stock News•1 hour ago

Micron (MU) Falls More Steeply Than Broader Market: What Investors Need to Know

Stock News•1 hour ago

Nvidia's $20 Billion Groq Bet Is Going Live Before the End of 2026. Here's What It Means for Investors.

Stock News•1 hour ago

Q2 Earnings Season Winds Down: 3 Companies That Broke Records